{"filing":{"accession_number":"0001104659-26-082875","cik":"0001999480","ticker":"ANRO","company_name":"Alto Neuroscience, Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"tm2620297d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926082875/tm2620297d1_8k.htm"},"events":[{"id":17488,"run_id":15664,"accession_number":"0001104659-26-082875","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"Alto Neuroscience announced acceleration and expansion of clinical development for ALTO-207, including an additional Phase 3 trial for treatment-resistant depression, representing a material strategic decision affecting the company's development trajectory and capital allocation.","company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":15985,"accession_number":"0001104659-26-082875","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The filing discloses two substantive items: (1) preliminary cash position of $244.2 million as of June 30, 2026, and (2) acceleration and expansion of clinical development for ALTO-207, including an additional Phase 3 trial for treatment-resistant depression. The pipeline update represents a material operational/strategic decision to accelerate a key clinical program, which would affect investor assessment of the company's development trajectory and capital allocation. While the cash disclosure is routine, the clinical development acceleration is the more salient material event disclosed in this Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:39:39.086924+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15984,"accession_number":"0001104659-26-082875","item_number":"2.02","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":false,"confidence":0.75,"reasoning":"Item 2.02 discloses \"Results of Operations and Financial Condition,\" but the actual content is merely a cross-reference to Item 8.01 regarding cash and cash equivalents as of June 30, 2026, with explicit disclaimers that the information is not \"filed\" and not incorporated by reference. This is a routine administrative disclosure of a balance-sheet item (cash position) rather than a substantive earnings release or material financial event. The lack of operational results, earnings metrics, or material financial developments, combined with the limited scope (cash position only) and the filing disclaimers, indicates this does not rise to materiality.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:39:39.086924+00:00","company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","filing_date":"2026-07-13"},{"id":15985,"accession_number":"0001104659-26-082875","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The filing discloses two substantive items: (1) preliminary cash position of $244.2 million as of June 30, 2026, and (2) acceleration and expansion of clinical development for ALTO-207, including an additional Phase 3 trial for treatment-resistant depression. The pipeline update represents a material operational/strategic decision to accelerate a key clinical program, which would affect investor assessment of the company's development trajectory and capital allocation. While the cash disclosure is routine, the clinical development acceleration is the more salient material event disclosed in this Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:39:39.086924+00:00","company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","filing_date":"2026-07-13"}]}